These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 15939340

  • 1. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B, Vega MI.
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [Abstract] [Full Text] [Related]

  • 2. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 3. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B.
    Cancer Res; 2005 Jan 01; 65(1):264-76. PubMed ID: 15665303
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 5. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B.
    Oncogene; 2007 May 28; 26(25):3629-36. PubMed ID: 17530016
    [Abstract] [Full Text] [Related]

  • 6. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.
    Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448
    [Abstract] [Full Text] [Related]

  • 7. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR, Bonavida B.
    Methods Mol Biol; 2011 Nov 01; 731():407-19. PubMed ID: 21516425
    [Abstract] [Full Text] [Related]

  • 8. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B.
    Oncogene; 2004 Apr 29; 23(20):3530-40. PubMed ID: 15077178
    [Abstract] [Full Text] [Related]

  • 9. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR, Vega MI, Bonavida B.
    Cancer Res; 2007 Feb 01; 67(3):1270-81. PubMed ID: 17283164
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 01; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 11. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ.
    Exp Hematol; 2007 Dec 01; 35(12):1801-11. PubMed ID: 17681667
    [Abstract] [Full Text] [Related]

  • 12. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS.
    Clin Cancer Res; 2008 Mar 01; 14(5):1550-60. PubMed ID: 18316580
    [Abstract] [Full Text] [Related]

  • 13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 01; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 01; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 15. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X, Hu W, Qin X.
    Oncologist; 2008 Sep 01; 13(9):954-66. PubMed ID: 18779537
    [Abstract] [Full Text] [Related]

  • 16. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 01; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 17. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
    Vega MI, Martínez-Paniagua M, Huerta-Yepez S, González-Bonilla C, Uematsu N, Bonavida B.
    Int J Oncol; 2009 Dec 01; 35(6):1289-96. PubMed ID: 19885551
    [Abstract] [Full Text] [Related]

  • 18. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [Abstract] [Full Text] [Related]

  • 19. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
    Suzuki E, Umezawa K, Bonavida B.
    Oncogene; 2007 Sep 13; 26(42):6184-93. PubMed ID: 17420722
    [Abstract] [Full Text] [Related]

  • 20. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.
    Int J Oncol; 2007 Jul 13; 31(1):29-40. PubMed ID: 17549402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.